Wang, J.-H.; Chen, Y.-Y.; Kee, K.-M.; Wang, C.-C.; Tsai, M.-C.; Kuo, Y.-H.; Hung, C.-H.; Li, W.-F.; Lai, H.-L.; Chen, Y.-H.
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers 2022, 14, 343.
https://doi.org/10.3390/cancers14020343
AMA Style
Wang J-H, Chen Y-Y, Kee K-M, Wang C-C, Tsai M-C, Kuo Y-H, Hung C-H, Li W-F, Lai H-L, Chen Y-H.
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers. 2022; 14(2):343.
https://doi.org/10.3390/cancers14020343
Chicago/Turabian Style
Wang, Jing-Houng, Yen-Yang Chen, Kwong-Ming Kee, Chih-Chi Wang, Ming-Chao Tsai, Yuan-Hung Kuo, Chao-Hung Hung, Wei-Feng Li, Hsiang-Lan Lai, and Yen-Hao Chen.
2022. "The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab" Cancers 14, no. 2: 343.
https://doi.org/10.3390/cancers14020343
APA Style
Wang, J.-H., Chen, Y.-Y., Kee, K.-M., Wang, C.-C., Tsai, M.-C., Kuo, Y.-H., Hung, C.-H., Li, W.-F., Lai, H.-L., & Chen, Y.-H.
(2022). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers, 14(2), 343.
https://doi.org/10.3390/cancers14020343
